<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DYNACIN- minocycline hydrochlorideÂ tabletÂ </strong><br>Par Pharmaceutical, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-3e2d4998-fa9c-4f5a-a6be-61156d9aea99"></a><a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride tablets and other antibacterial drugs, minocycline hydrochloride tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="inv-7486a8e6-9504-4103-bad8-bff3f9aa77a7"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)â€‘1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2â€‘naphthacenecarboxamide monohydrochloride.  Its structural formula is:</p>
<div class="Figure">
<a name="ID0E6OAC"></a><img alt="this is the structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f174edbd-3ac0-4e27-a116-3b74804721bb&amp;name=structure.jpg">
</div>
<p>C<span class="Sub">23</span>H<span class="Sub">27</span>N<span class="Sub">3</span>O<span class="Sub">7 </span>Î‡HCl </p>
<p>M.W.  493.94</p>
<p>Minocycline hydrochloride tablets for oral administration contain minocycline HCl equivalent to 50 mg, 75 mg or 100 mg of minocycline.  In addition, 50 mg, 75 mg and 100 mg tablets contain the following inactive ingredients: Microcrystalline Cellulose NF, Lactose Anhydrous NF, Povidone USP, Colloidal Silicon Dioxide NF, Magnesium Stearate NF, and Sodium Starch Glycolate NF. The 50 mg, 75 mg and 100 mg tablets also contain Opadry White which contains: Titanium Dioxide USP, Hypromellose Type 2910 USP, Polyethylene Glycol 400 NF, and Polysorbate 80 NF. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="inv-0646d9eb-008f-4f8a-8884-0332ee4fc82f"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Following a single dose of one 100 mg tablet of minocycline hydrochloride administered to 28 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 3 hours (average 1.71 hours) and ranged from 491.71 to 1292.70 ng/mL (average 758.29 ng/mL).  The serum half-life in the normal volunteers ranged from 11.38 to 24.31 hours (average 17.03 hours). </p>
<p>When minocycline hydrochloride tablets were given concomitantly with a meal, which included dairy products, the extent of absorption of minocycline hydrochloride tablets was slightly decreased (6%).  The peak plasma concentrations were slightly decreased (12%) and delayed by 1.09 hours when administered with food, compared to dosing under fasting conditions.  Minocycline HCl may be administered with or without food.</p>
<p>In previous studies with other minocycline dosage forms, the minocycline serum half-life ranged from 11 to 16 hours in 7 patients with hepatic dysfunction, and from 18 to 69 hours in 5 patients with renal dysfunction. The urinary and fecal recovery of minocycline when administered to 12 normal volunteers was one-half to one-third that of other tetracyclines. </p>
<div class="Section" data-sectionCode="49489-8">
<a name="inv-f11eda34-b275-409b-b6fb-91a2417e1abb"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis.  The tetracyclines, including minocycline, have similar antimicrobial spectra of activity against a wide range of gram-positive and gram-negative organisms.  Cross-resistance of these organisms to tetracycline is common.  </p>
<p>Minocycline has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND USAGE</span> section: </p>
<p>AEROBIC GRAM-POSITIVE MICROORGANISMS </p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following gram-positive microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are especially recommended.  Tetracycline antibiotics should not be used for streptococcal diseases unless the organism has been demonstrated to be susceptible.  Tetracyclines are not the drug of choice in the treatment of any type of <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infection</span>. </p>
<p><span class="Italics">Bacillus anthracis</span><span class="Sup">a </span></p>
<p><span class="Italics">Listeria monocytogenes</span><span class="Sup">a </span></p>
<p><span class="Italics">Staphylococcus aureu</span>s  </p>
<p><span class="Italics">Streptococcus <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></span>e   </p>
<p>AEROBIC GRAM-NEGATIVE MICROORGANISMS </p>
<p><span class="Italics">Bartonella bacilliformi</span>s  </p>
<p><span class="Italics">Brucella </span>species </p>
<p><span class="Italics">Calymmatobacterium granulomati</span>s  </p>
<p><span class="Italics">Campylobacter fetu</span>s  </p>
<p><span class="Italics">Francisella tularensi</span>s  </p>
<p><span class="Italics">Haemophilus ducrey</span>i </p>
<p><span class="Italics">Vibrio <span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">cholera</span></span>e  </p>
<p><span class="Italics">Yersinia pesti</span>s   </p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility tests are especially recommended. </p>
<p><span class="Italics">Acinetobacter </span>species  </p>
<p><span class="Italics">Enterobacter aerogene</span>s </p>
<p><span class="Italics">Escherichia col</span>i </p>
<p><span class="Italics">Haemophilus <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span></span>e </p>
<p><span class="Italics">Klebsiella </span>species  </p>
<p><span class="Italics">Neisseria gonorrhoeae</span><span class="Sup"> a </span></p>
<p><span class="Italics">Neisseria meningitidis</span><span class="Sup"> a </span></p>
<p>â€œOTHERâ€? MICROORGANISMS </p>
<p><span class="Italics">Actinomyces</span> species<span class="Sup">a</span></p>
<p><span class="Italics">Borrelia recurrentis </span></p>
<p><span class="Italics"> Chlamydia psittaci </span></p>
<p><span class="Italics">Chlamydia trachomatis </span></p>
<p><span class="Italics">Clostridium</span> species<span class="Sup"> a</span></p>
<p><span class="Italics">Entamoeba</span> species </p>
<p><span class="Italics">Fusobacterium nucleatum </span>subspecies<span class="Italics"> fusiforme</span><span class="Sup">a </span></p>
<p><span class="Italics">Mycobacterium marinum </span></p>
<p><span class="Italics">Mycoplasma <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></span>e</p>
<p><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></span>s</p>
<p><span class="Italics">Rickettsia</span>e  </p>
<p><span class="Italics">Treponema pallidum </span>subspecies <span class="Italics">pallidum</span><span class="Sup"> a </span></p>
<p><span class="Italics">Treponema pallidum </span>subspecies<span class="Italics"> pertenue</span><span class="Sup"> a </span></p>
<p><span class="Italics">Ureaplasma urealyticum </span></p>
<p><span class="Sup">a </span>When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the cited microorganisms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-3db39436-4c0b-489c-8ced-69c660942619"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Tests</h2>
<p class="First">Susceptibility testing should be performed with tetracycline since it predicts susceptibility to minocycline.  However, certain organisms (e.g., some staphylococci, and <span class="Italics">Acinetobacter </span>species) may be more susceptible to minocycline and doxycycline than to tetracycline. </p>
<p><span class="Italics">Dilution techniques: </span></p>
<p>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure.  Standardized procedures are based on a dilution method<span class="Sup">1,3</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of tetracycline powder.  The MIC values should be interpreted according to the following criteria:</p>
<p>For testing aerobic gram-negative microorganisms (Enterobacteriaceae), <span class="Italics">Acinetobacter</span> species and <span class="Italics">Staphylococcus aereus</span>:</p>
<table width="100%">
<col width="25%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 16</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p>For testing <span class="Italics">Haemophilusinfluenza<span class="Sup">b</span></span>and <span class="Italics">Streptococcus <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span><span class="Sup">c:</span></span></p>
<table width="100%">
<col width="25%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">b</span>These interpretative standards are applicable only to broth microdilution susceptibility testing with <span class="Italics">Haemophilus influenzae </span>using <span class="Italics">Haemophilus</span> Test Medium.<span class="Sup">1</span></p>
<p><span class="Sup">c</span>These interpretative standards are applicable only to broth microdilution susceptibility testing using cation-adjusted Muller-Hinton broth with 2 â€“ 5% lysed horse blood.<span class="Sup">1 </span></p>
<p>For testing <span class="Italics">Neisseria gonorrhoeae<span class="Sup">d</span> :</span></p>
<table width="100%">
<col width="25%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 0.25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 - 1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">d</span>These interpretative standards are applicable only to agar dilution susceptibility testing using GC agar base and 1% defined growth supplements.<span class="Sup">1</span></p>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable.  A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected. </p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.  Standard tetracycline powder should provide the following MIC values: </p>
<table width="100%">
<col width="40%">
<col width="24%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"><span class="Underline">Microorganism</span></span></p></td>
<td class="Botrule Rrule Toprule"><p class="First">Â </p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Escherichia coli</span></p></td>
<td class="Botrule Rrule"><p class="First">ATCC 25922 </p></td>
<td class="Botrule Rrule"><p class="First">0.5-2 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Enterococcus faecalis</span></p></td>
<td class="Botrule Rrule"><p class="First">ATCC 29212 </p></td>
<td class="Botrule Rrule"><p class="First">8-32 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Staphylococcus aureus</span></p></td>
<td class="Botrule Rrule"><p class="First">ATCC 29213 </p></td>
<td class="Botrule Rrule"><p class="First">0.25-1 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Haemophilus influenzae</span></p></td>
<td class="Botrule Rrule"><p class="First">ATCC 49247 </p></td>
<td class="Botrule Rrule"><p class="First">4-32 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Streptococcus pneumoniae</span></p></td>
<td class="Botrule Rrule"><p class="First">ATCC 49619 </p></td>
<td class="Botrule Rrule"><p class="First">0.12-0.5 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Neisseria gonorrhoeae</span></p></td>
<td class="Botrule Rrule"><p class="First">ATCC 49226 </p></td>
<td class="Botrule Rrule"><p class="First">0.25-1 </p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Diffusion techniques: </span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3 </span>requires the use of standardized inoculum concentrations.  This procedure uses paper disks impregnated with 30 mcg tetracycline (class disk) or 30 mcg minocycline to test the susceptibility of microorganisms to minocycline.   </p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg tetracycline or minocycline disk should be interpreted according to the following criteria: </p>
<p>For testing aerobic gram-negative microorganisms (Enterobacteriaceae), <span class="Italics">Acinetobacter</span> species and <span class="Italics">Staphylococcus aureus: </span></p>
<table width="100%">
<col width="32%">
<col width="32%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 19</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15-18</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p>For testing <span class="Italics">Haemophilus influenzae</span><span class="Sup">e</span>: </p>
<table width="100%">
<col width="32%">
<col width="32%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 29</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26-28</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">e</span> These zone diameter standards are applicable only to susceptibility testing with <span class="Italics">Haemophilus influenzae </span>using <span class="Italics">Haemophilus </span>Test Medium and 30 mcg tetracycline disk.<span class="Sup">2</span></p>
<p>For testing <span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">f</span>: </p>
<table width="100%">
<col width="32%">
<col width="32%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 38</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31-37</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 30</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">f </span> These interpretative standards are applicable only to disk diffusion testing </p>
<p>using GC agar and 1% growth supplements, and a 30 mcg tetracycline disk.<span class="Sup">2</span></p>
<p>For testing <span class="Italics">Streptococcus pneumoniae</span><span class="Sup">g</span>: </p>
<table width="100%">
<col width="32%">
<col width="32%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 23</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19-22</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 18</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">g</span>These interpretative standards are applicable only to disk diffusion testing using Muller-Hinton agar adjusted with 5% sheep blood and a 30 mcg tetracycline disk.<span class="Sup">2</span></p>
<p>For testing <span class="Italics">Vibrio cholerae</span><span class="Sup">h</span>: </p>
<table width="100%">
<col width="32%">
<col width="32%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Interpretation</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¥ 19</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15-18</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">â‰¤ 14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">h </span>These interpretative standards are applicable only to disk diffusion testing performed with a 30 mcg tetracycline disk.<span class="Sup">2</span></p>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for tetracycline. </p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 mcg tetracycline or minocycline disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>: </p>
<table width="100%">
<col width="37%">
<col width="23%">
<col width="21%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"><span class="Underline">Microorganism</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Â </span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Zone Diameter</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Underline">Range (mm)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â </p></td>
<td class="Botrule Rrule" align="center"><p class="First">Â </p></td>
<td class="Botrule Rrule" align="center"><p class="First">Tetracycline</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Minocycline</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Escherichia coli</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">ATCC25922</p></td>
<td class="Botrule Rrule" align="center"><p class="First">18-25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19-25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Staphylococcus aureus</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">ATCC 29213</p></td>
<td class="Botrule Rrule" align="center"><p class="First">24-30</p></td>
<td class="Botrule Rrule" align="center"><p class="First">25-30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Haemophilus influenzae</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">ATCC 49247</p></td>
<td class="Botrule Rrule" align="center"><p class="First">14-22</p></td>
<td class="Botrule Rrule" align="center"><p class="First">---</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Neisseria gonorrhoeae</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">ATCC 49226</p></td>
<td class="Botrule Rrule" align="center"><p class="First">30-42</p></td>
<td class="Botrule Rrule" align="center"><p class="First">---</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Streptococcus pneumoniae </p></td>
<td class="Botrule Rrule" align="center"><p class="First">ATCC 49619</p></td>
<td class="Botrule Rrule" align="center"><p class="First">27-31</p></td>
<td class="Botrule Rrule" align="center"><p class="First">---</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="inv-30165949-ce36-453a-b139-1fe663d3622c"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Minocycline hydrochloride tablets are indicated in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms: </p>
<dl>
<dt>â€¢</dt>
<dd>Rocky Mountain spotted <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, typhus <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and the typhus group, Q <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, rickettsialpox and tick <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> caused by <span class="Italics">Rickettsiae</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Mycoplasma pneumoniae</span>.</dd>
<dt>â€¢</dt>
<dd>Lymphogranuloma venereum caused by <span class="Italics">Chlamydia trachomatis</span>.</dd>
<dt>â€¢</dt>
<dd>Psittacosis (Ornithosis) due to Chlamydia psittaci.</dd>
<dt>â€¢</dt>
<dd>Trachoma caused by <span class="Italics">Chlamydia trachomatis</span>, although the infectious agent is not always eliminated, as judged by immunofluorescence. </dd>
<dt>â€¢</dt>
<dd>Inclusion <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by <span class="Italics">Chlamydia trachomatis</span>.</dd>
<dt>â€¢</dt>
<dd>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span>, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults caused by <span class="Italics">Ureaplasma urealyticum</span> or <span class="Italics">Chlamydia trachomatis</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span> due to <span class="Italics">Borrelia recurrentis</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">Chancroid</span> caused by <span class="Italics">Haemophilus ducreyi</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> due to <span class="Italics">Yersinia pestis</span>.</dd>
<dt>â€¢</dt>
<dd>Tularemia due to <span class="Italics">Francisella tularensis.</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">Cholera</span> caused by <span class="Italics">Vibrio cholerae.</span>
</dd>
<dt>â€¢</dt>
<dd>Campylobacter fetus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Campylobacter fetus.</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">Brucellosis</span> due to <span class="Italics">Brucella</span> species (in conjunction with streptomycin). </dd>
<dt>â€¢</dt>
<dd>Bartonellosis due to <span class="Italics">Bartonella bacilliformis</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">Granuloma inguinale</span> caused by <span class="Italics">Calymmatobacterium granulomatis.</span>
</dd>
</dl>
<p>Minocycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Italics">Escherichia coli.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Enterobacter aerogenes</span>. </dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Shigella</span> species. </dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Acinetobacter</span> species. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infection</span> caused by <span class="Italics">Haemophilus influenzae.</span>
</dd>
<dt>â€¢</dt>
<dd>Respiratory tract and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> cause by <span class="Italics">Kiebsiella</span> species.</dd>
</dl>
<p>Minocycline hydrochloride tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> caused by <span class="Italics">Streptococcus pneumoniae</span>
</dd>
<dt>â€¢</dt>
<dd>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Staphylococcus aureus</span>.  (Note: Minocycline is not the drug of choice in the treatment of any type of <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infection</span>).</dd>
</dl>
<p>When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<dl>
<dt>â€¢</dt>
<dd>Uncomplicated <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> in men due to <span class="Italics">Neisseria gonorrhoeae</span> and for the treatment of other gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in women caused by <span class="Italics">Neisseria gonorrhoeae.</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> caused by <span class="Italics">Treponema pallidum</span> subspecies <span class="Italics">pallidum</span>. </dd>
<dt>â€¢</dt>
<dd>Yaws caused by <span class="Italics">Treponema pallidum</span> subspecies <span class="Italics">pertenue</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> due to <span class="Italics">Listeria monocytogenes</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> due to <span class="Italics">Bacillus anthracis</span>. </dd>
<dt>â€¢</dt>
<dd>Vincentâ€™s <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Fusobacterium fusiforme</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> caused by <span class="Italics">Actinomyces israelii</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by <span class="Italics">Clostridium</span> species.</dd>
</dl>
<p>In acute<span class="Italics"> intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span></span>, minocycline may be  a useful adjunct to amebicides.</p>
<p>In severe <span class="Italics"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></span>, minocycline may be useful adjunctive therapy.</p>
<p>Oral minocycline is indicated in the treatment of asymptomatic carriers of <span class="Italics">Neisseria meningitidis </span>to eliminate the meningococci from the nasopharynx.  In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of minocycline be reserved for situations in which the risk of <span class="product-label-link" type="condition" conceptid="438338" conceptname="Meningococcal meningitis">meningococcal meningitis</span> is high. </p>
<p><span class="Italics">Oral minocycline is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436621" conceptname="Meningococcal infectious disease">meningococcal infection</span></span>. </p>
<p>Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Mycobacterium marinum</span>.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness ofminocycline hydrochloride tablets and other antibacterial drugs, minocycline hydrochloride tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="inv-b6908e30-c7ca-4da3-a3a2-f4dc850c26b7"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines or to any of the components of the product formulation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="inv-01bdda71-1631-40ed-a5b2-c7b0cf70259d"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">MINOCYCLINE HYDROCHLORIDE TABLETS, LIKE OTHER TETRACYCLINE CLASS ANTIBIOTICS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW â€“ GRAY-BROWN). </span></p>
<p>This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported. <span class="Bold">TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.</span></p>
<p>All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every six hours.  This reaction was shown to be reversible when the drug was discontinued. </p>
<p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has been noted in animals treated early in pregnancy. </p>
<p><span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">Drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS) including fatal cases have been reported with minocycline use.  If this syndrome is recognized, the drug should be discontinued immediately.</p>
<p>The anti-anabolic action of the tetracyclines may cause an increase in BUN.  While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline may lead to <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. Under such conditions, monitoring of creatinine and BUN is recommended, and the total daily dosage should not exceed 200 mg in 24 hours (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>). If <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> exists, even usual oral or parenteral doses may lead to systemic accumulation of the drug and possible liver toxicity. </p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported with minocycline. </p>
<p>Central nervous system side effects including light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually disappear rapidly when the drug is discontinued. </p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including minocycline hydrochloride, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>. </p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="inv-1be45be3-2e98-4fa6-934f-52b924763042"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold">General</span>: As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, the antibiotic should be discontinued and appropriate therapy instituted.</p>
<p><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>) in adults has been associated with the use of tetracyclines. The usual clinical manifestations are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Bulging fontanels have been associated with the use of tetracyclines in infants.  While both of these conditions and related symptoms usually resolve after discontinuation of the tetracycline, the possibility for permanent sequelae exists. </p>
<p>Hepatotoxicity has been reported with minocycline; therefore, minocycline should be used with caution in patients with hepatic dysfunction and in conjunction with other hepatotoxic drugs. </p>
<p>Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy when indicated. </p>
<p>Prescribing minocycline hydrochloride tablets in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. </p>
<div class="Section" data-sectionCode="34076-0">
<a name="inv-906a97ac-64a1-4d0d-804e-c79fe3859c20"></a><a name="section-7.1"></a><p></p>
<h2>Information For Patients</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. </p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>. This reaction has been reported with use of minocycline. </p>
<p>Patients who experience central nervous system symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy (see <span class="Bold">WARNINGS</span>). </p>
<p>Concurrent use of tetracycline with oral contraceptives may render oral contraceptives less effective (see <span class="Bold">Drug Interactions</span>). </p>
<p>Patients should be counseled that antibacterial drugs including minocycline hydrochloride tablets should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When minocycline hydrochloride tablets are prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by minocycline hydrochloride tablets or other antibacterial drugs in the future. </p>
<p>Unused supplies of tetracycline antibiotics should be discarded by the expiration date. </p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="inv-13c1c94b-2176-437d-960e-4b02befa3990"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In venereal disease when coexistent <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months. </p>
<p>Periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic, should be performed. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="inv-9277723a-9e78-46d2-98ed-056c1b73f5ed"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Because tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. </p>
<p>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. </p>
<p>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations. </p>
<p>The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.</p>
<p>Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. </p>
<p>Administration of isotretinoin should be avoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (see PRECAUTIONS). </p>
<p>Increased risk of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> when ergot alkaloids or their derivatives are given with tetracyclines. </p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="inv-964410e5-190b-475f-9ad4-8a4fbe19ab6c"></a><a name="section-7.4"></a><p></p>
<h2>Drug and/or Laboratory Test Interactions</h2>
<p class="First">False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="inv-8662af5d-f32b-4754-bc7c-525c6b5531ee"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First">Dietary administration of minocycline in long term tumorigenicity studies in rats resulted in evidence of <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumor</span> production. Minocycline has also been found to produce <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in rats and dogs. In addition, there has been evidence of oncogenic activity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Likewise, although mutagenicity studies of minocycline have not been conducted, positive results in in vitro mammalian cell assays (i.e., mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and Chinese hamster lung cells) have been reported for related antibiotics (tetracycline hydrochloride and oxytetracycline). Segment I (fertility and general reproduction) studies have provided evidence that minocycline impairs fertility in male rats. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="inv-b39c979d-ba63-4ced-802a-5d56b29be43d"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects: Pregnancy Category D </span>(see <span class="Bold">WARNINGS</span>). </p>
<p>All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class antibiotics, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported in post-marketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can be established. If minocycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. </p>
<p><span class="Italics">Nonteratogenic Effects: </span>(see <span class="Bold">WARNINGS</span>). </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="inv-fc94f415-f16b-4fd0-bebd-1e40f56004ea"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of tetracyclines on labor and delivery is unknown. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="inv-6ed5ce0e-65dd-43cc-b9b3-168939b76ed2"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS). </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="inv-1a7d3067-8d64-4ce4-a9a6-3217258bf5e2"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Minocycline is not recommended for use in children below 8 years of age unless the expected benefits of therapy outweigh the risks (see WARNINGS). </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="inv-060ba892-2e2f-4ac3-8b42-f6a0c833bbcc"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of oral minocycline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see WARNINGS, DOSAGE AND ADMINISTRATION). </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-07e442dd-ab22-462c-8b6d-d5b9186d7c95"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Due to oral minocyclineâ€™s virtually complete absorption, side effects to the lower bowel, particularly <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines. </p>
<p><span class="Italics">Body as a whole: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, and discoloration of secretions. </p>
<p><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">enamel hypoplasia</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions. Instances of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcerations</span> have been reported in patients taking the tetracycline-class antibiotics in capsule and tablet form. Most of these patients took the medication immediately before going to bed (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>). </p>
<p><span class="Italics">Genitourinary: </span><span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">Vulvovaginitis</span>. </p>
<p><span class="Italics">Hepatic toxicity: </span><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>, hepatic <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, increases in liver enzymes, fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, including <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> have been reported (see <span class="Bold">PRECAUTIONS</span>). </p>
<p><span class="Italics">Skin: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, hyperpigmentation of nails, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>. Maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> has been reported. <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">Fixed drug eruptions</span> have been reported. Lesions occurring on the glans penis have caused <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span>. <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> have been reported. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed above (see <span class="Bold">WARNINGS</span>). <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> of the skin and mucous membranes has been reported. </p>
<p><span class="Italics">Respiratory: </span><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, and <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>. </p>
<p><span class="Italics">Renal toxicity: </span>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>. Elevations in BUN have been reported and are apparently dose related (see <span class="Bold">WARNINGS</span>). Reversible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported. </p>
<p><span class="Italics">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, bone discoloration, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, and <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">polyarthralgia</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>/anaphylactoid  reaction (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and fatalities), <span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and pulmonary infiltrates with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported. A transient lupus-like syndrome and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions also have been reported. </p>
<p><span class="Italics">Blood: </span><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported. </p>
<p><span class="Italics">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, sedation, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) in adults have been reported (see <span class="Bold">PREâ€‘CAUTIONSâ€”General</span>). <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> has also been reported. </p>
<p><span class="Italics">Other: </span>Thyroid cancer has been reported in the post-marketing setting in association with minocycline products.  When minocycline therapy is given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, monitoring for signs of thyroid cancer should be considered.  When given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. Cases of abnormal thyroid function have been reported. </p>
<p><span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> in children less than 8 years of age, and also in adults, has been reported (see <span class="Bold">WARNINGS</span>). </p>
<p>Oral cavity discoloration (including tongue, lip, and gum) have been reported. </p>
<p><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> and decreased hearing have been reported in patients on minocycline hydrochloride. </p>
<p>The following syndromes have been reported. In some cases involving these syndromes, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported. As with other serious adverse reactions, if any of these syndromes are recognized, the drug should be discontinued immediately:</p>
<p><span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">Hypersensitivity syndrome</span> consisting of cutaneous reaction (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>), <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and one or more of the following: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, and <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> may be present. </p>
<p>Lupus-like syndrome consisting of positive <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, or <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; and one or more of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span>-like syndrome consisting of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, or <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> may be present. </p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="inv-1e5c1a0b-332b-428e-a714-5b1f826487ca"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE</h1>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="inv-688778e8-52bf-4b3f-8ae9-8c67bd7cd2c2"></a><a name="section-10"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">DRUG DEPENDENCE</span></h1>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="inv-6e6ebbff-ee2b-4b13-b5c8-2a48707af1eb"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The adverse events more commonly seen in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>No specific antidote for minocycline is known. </p>
<p>In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="inv-8263a877-434f-45f2-87a5-f3af05e13a8f"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF MINOCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS. </span></p>
<p>Minocycline hydrochloride tablets may be taken with or without food (see <span class="Bold">CLINICAL PHARMACOLOGY</span>). </p>
<p>Ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline-class is recommended to reduce </p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-8a93a985-c50b-4a3f-b556-9a7361725e10"></a><a name="section-12.1"></a><p></p>
<h2>For Pediatric Patients Above 8 Years of Age</h2>
<p class="First">Usual pediatric dose: 4 mg/kg initially followed by 2 mg/kg every 12 hours, not to exceed the usual adult dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-cc0c94d9-e79f-4cfd-839a-9295a994e6ab"></a><a name="section-12.2"></a><p></p>
<h2>Adults</h2>
<p class="First">The usual dosage of minocycline hydrochloride tablets is 200 mg initially followed by 100 mg every 12 hours. Alternatively, if more frequent doses are preferred, two or four 50 mg tablets may be given initially followed by one 50 mg tablet four times daily. </p>
<p>Uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> and anorectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in men: 200 mg initially, followed by 100 mg every 12 hours for a minimum of four days, with post-therapy cultures within 2 to 3 days. </p>
<p>In the treatment of uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> in men, 100 mg every 12 hours for 5 days is recommended. </p>
<p>For the treatment of <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, the usual dosage of minocycline hydrochloride should be administered over a period of 10 to 15 days. Close follow-up, including laboratory tests, is recommended. </p>
<p>In the treatment of meningococcal carrier state, the recommended dosage is 100 mg every 12 hours for five days. </p>
<p><span class="Italics">Mycobacterium marinum </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: Although optimal doses have not been established, 100 mg every 12 hours for 6 to 8 weeks have been used successfully in a limited number of cases. </p>
<p>Uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults caused by <span class="Italics">Chlamydia trachomatis </span>or <span class="Italics">Ureaplasma urealyticum</span>: 100 mg orally, every 12 hours for at least seven days. </p>
<p>Ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline-class is recommended to reduce the risk of esophageal irritation and ulceration. </p>
<p>The pharmacokinetics of minocycline in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR </span>&lt;80mL/min) have not been fully characterized.  Current data are insufficient to determine if a dosage adjustment is warranted. The total daily dosage should not exceed 200 mg in 24 hours. However, due to the anti-anabolic effect of tetracyclines, BUN and creatinine should be monitored (see <span class="Bold">WARNINGS</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="inv-b528688d-4307-4830-9863-e3ddc8a0c9f7"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Minocycline hydrochloride tablets are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 50 mg, 75 mg and 100 mg minocycline. </p>
<p>The 50 mg tablets are white, unscored, modified capsule shaped, coated tablet debossed with  â€œParâ€? on one side and â€œ511â€? on the other. Each tablet contains minocycline hydrochloride equivalent to 50 mg minocycline, supplied as follows: </p>
<p>NDC49884-096-01	Bottle of 100 </p>
<p>The 75 mg tablets are white, unscored, modified capsule shaped, coated tablet debossed with â€œParâ€? on one side and â€œ512â€? on the other. Each tablet contains minocycline hydrochloride equivalent to 75 mg minocycline, supplied as follows: </p>
<p>NDC49884-097-01	Bottle of 100 </p>
<p>The 100 mg tablets are white, unscored, modified capsule shaped, coated tablet debossed with â€œParâ€? on one side and â€œ513â€? on the other. Each tablet contains minocycline hydrochloride equivalent to 100 mg minocycline, supplied as follows: </p>
<p>NDC49884-098-03	Bottle of 50</p>
<p>Store at 20 to 25ÂºC (68Âº to 77ÂºF) [See USP Controlled Room Temperature]</p>
<p>Protect from light, moisture, and excessive heat. </p>
<p>Dispense in a tight, light-Â¬resistant container as defined in the USP. Text Here</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="inv-25ccb185-77d6-4f26-a24a-6be4c292c754"></a><a name="section-14"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND/OR TOXICOLOGY</h1>
<p class="First">Minocycline hydrochloride has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline hydrochloride has resulted in <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> accompanied by elevated radioactive iodine uptake and evidence of <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumor</span> production. Minocycline hydrochloride has also been found to produce <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in rats and dogs. </p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="inv-2883f396-1488-4c80-8ab8-63e35b986345"></a><a name="section-15"></a><p></p>
<h1>CLINICAL STUDIES</h1>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="inv-e58577c2-3040-4185-ae57-15231abcac49"></a><a name="section-16"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically â€“ Fourth Edition; Approved Standard. NCCLS Document M7-A4, Vol. 17, No. 2, NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA. January 1997. </p>
<p>2. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disk Susceptibility Tests â€“ Sixth Edition; Approved Standard. NCCLS Document M2-A6, Vol. 17, No.1, NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA.January 1997. </p>
<p>3. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Tests â€“ Eighth Edition; Approved Standard. NCCLS Document M100-S8, Vol. 18, No. 1, NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA. January 1998.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="inv-031ba21c-eac6-4114-be72-f8ccef179db2"></a><a name="section-17"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"><span class="Bold">DYNACIN<span class="Sup">Â® </span></span>[dÄ«-na-sÄ­n]  </p>
<p>(Minocycline Hydrochloride Tablets, USP)</p>
<p>50mg, 75mg, and 100 mg</p>
<p>Read the Patient Information that comes with DYNACIN<span class="Sup">Â® </span>Tablets before you or a family member starts taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment. </p>
<p><span class="Bold">What is DYNACIN<span class="Sup">Â®</span>? </span></p>
<p>DYNACIN<span class="Sup">Â® </span>is a tetracycline-class antibiotic medicine. DYNACIN<span class="Sup">Â® </span>is used to treat certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria. These include <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the skin, respiratory tract, urinary tract, some <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>, and others. DYNACIN<span class="Sup">Â® </span>may be used along with other treatments for severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. </p>
<p>Sometimes, other germs, called viruses cause <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> is a virus. DYNACIN<span class="Sup">Â®</span>, like other antibiotics, does not treat viruses. </p>
<p><span class="Bold">Who should not use DYNACIN<span class="Sup">Â®</span>? </span></p>
<p><span class="Bold">Do not take DYNACIN<span class="Sup">Â® </span>if you are allergic to minocycline or other tetracycline antibiotics. </span></p>
<p>Ask your doctor or pharmacist for a list of these medications if you are not sure. See the end of this leaflet for a complete list of ingredients in DYNACIN<span class="Sup">Â®</span>. </p>
<p><span class="Bold">DYNACIN<span class="Sup">Â® </span>is not recommended for pregnant women or children up to 8 years old because: </span></p>
<dl>
<dt>1.</dt>
<dd>DYNACIN<span class="Sup">Â®</span> may harm an unborn baby. </dd>
<dt>2.</dt>
<dd>DYNACIN<span class="Sup">Â®</span> may permanently turn a babyâ€™s or childâ€™s teeth yellowÂ¬grayÂ¬brown during tooth development. Tooth development happens in the last half of pregnancy and birth to age 8years. </dd>
</dl>
<p><span class="Bold">What should I tell my doctor before starting DYNACIN<span class="Sup">Â® </span>Tablets? </span></p>
<p>Tell your doctor about all of your medical conditions, including if you: </p>
<dl>
<dt>â€¢</dt>
<dd>Have liver or kidney problems. </dd>
<dt>â€¢</dt>
<dd>Are pregnant or planning to become pregnant. DYNACIN<span class="Sup">Â®</span> may harm your unborn baby. Stop taking DYNACIN<span class="Sup">Â®</span> and call your doctor if you become pregnant while taking it. </dd>
<dt>â€¢</dt>
<dd>Are breast feeding. DYNACINÂ® passes into your milk and may harm your baby. You should decide whether to use DYNACIN<span class="Sup">Â®</span> or breastfeed, but not both. </dd>
</dl>
<p>Tell your doctor about all the medicines you are taking including prescription and non prescription medications, vitamins, and herbal supplements. DYNACIN<span class="Sup">Â® </span>and other medicines may interact. Especially tell your doctor if you take: </p>
<dl>
<dt>â€¢</dt>
<dd>birth control pills. DYNACIN<span class="Sup">Â®</span> may make your birth control pills less effective. </dd>
<dt>â€¢</dt>
<dd>A blood thinner medicine. The dose of your blood thinner may have to be lowered. </dd>
<dt>â€¢</dt>
<dd>A penicillin antibiotic medicine. DYNACIN<span class="Sup">Â®</span> and penicillins should not be used together. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> medicines called ergot alkaloids.</dd>
<dt>â€¢</dt>
<dd>An <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> medicine called isotretinoin (Accutane<span class="Sup">Â®</span>, Amnesteem<span class="Sup">Â®</span>, Claravis<span class="Sup">Â®</span>, Sotret<span class="Sup">Â®</span>). </dd>
<dt>â€¢</dt>
<dd>Antacids that contain aluminum, calcium, or magnesium, or iron-containing products. </dd>
</dl>
<p>Know the medicines you take, keep a list of them to show your doctor and pharmacist each time you get a new medicine. </p>
<p><span class="Bold">How should I take DYNACIN<span class="Sup">Â® </span>Tablets? </span></p>
<dl>
<dt>â€¢</dt>
<dd>Take DYNACINÂ® Tablets exactly as your doctor tells you to take them. Skipping doses or not taking all your DYNACIN<span class="Sup">Â®</span> may:<dl>
<dt>â€¢</dt>
<dd>Decrease the effectiveness of the treatment. </dd>
<dt>â€¢</dt>
<dd>Increase the chance that bacteria will develop resistance to DYNACIN<span class="Sup">Â®</span>. </dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Take DYNACINÂ®with a full glass of liquid. Taking DYNACIN<span class="Sup">Â®</span> with enough liquid may lower your chance of getting irritation or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in your esophagus. Your esophagus is the tube that connects your mouth to your stomach. </dd>
<dt>â€¢</dt>
<dd>DYNACIN<span class="Sup">Â®</span> Tablets may be taken with or without food. If you forget to take DYNACIN<span class="Sup">Â®</span>, take it as soon as you remember. </dd>
<dt>â€¢</dt>
<dd>If you take too much DYNACIN<span class="Sup">Â®</span>, call you doctor or poison control center right away. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of DYNACIN<span class="Sup">Â®</span>? </span></p>
<p><span class="Bold">DYNACIN<span class="Sup">Â® </span>may cause serious side effects. Stop DYNACIN<span class="Sup">Â®</span> and call your doctor if you have:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> </dd>
<dt>â€¢</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> </dd>
<dt>â€¢</dt>
<dd>feeling very tired </dd>
</dl>
<p><span class="Bold">DYNACIN<span class="Sup">Â® </span>may also cause: </span></p>
<dl>
<dt>â€¢</dt>
<dd>central nervous system effects. Symptoms include light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and a spinning feeling (<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>). You should not drive or operate machines if you have these symptoms. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">sun sensitivity</span> (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>). You may get a worse sunburn with DYNACINÂ®. Avoid sun exposure and the use of sunlamps or tanning beds. Protect your skin while out in the sunlight. Stop DYNACINÂ® and call your doctor if your skin turns red. </dd>
</dl>
<p>These are not all the side effects with DYNACIN<span class="Sup">Â®</span>. Ask your doctor or pharmacist for more information. </p>
<p><span class="Bold">How should I store DYNACIN<span class="Sup">Â® </span>Tablets? </span></p>
<dl>
<dt>â€¢</dt>
<dd>Store DYNACINÂ® Tablets at room temperature and away from excess heat and moisture. </dd>
<dt>â€¢</dt>
<dd>Throw away any DYNACINÂ® that is outdated or no longer needed. </dd>
<dt>â€¢</dt>
<dd>Keep DYNACINÂ® Tablets and all medicines out of the reach of children. </dd>
</dl>
<p><span class="Bold">General advice about DYNACIN<span class="Sup">Â® </span>Tablets </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use DYNACIN<span class="Sup">Â® </span>Tablets for a condition for which it was not prescribed. Do not give DYNACIN<span class="Sup">Â® </span>Tablets to other people, even if they have the same symptoms you have. It may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about DYNACIN<span class="Sup">Â®</span>. If you would like more information, talk with your doctor. </p>
<p>Your doctor or pharmacist can give you information about DYNACIN<span class="Sup">Â® </span>that is written for health care professionals. For more information, you can also call Par Pharmaceutical at 1-800-828-9393. </p>
<p><span class="Bold">What are the ingredients in DYNACIN<span class="Sup">Â® </span>Tablets? </span></p>
<p><span class="Bold">Active ingredient: </span>minocycline hydrochloride, 50 mg, 75 mg, and 100 mg </p>
<p><span class="Bold">Inactive ingredients: </span>Microcrystalline Cellulose NF, Lactose Anhydrous NF, Povidone USP, Colloidal Silicon Dioxide NF, Magnesium Stearate NF, and Sodium Starch Glycolate NF. The 50 mg, 75 mg and 100 mg tablets also contain Opadry White which contains:  Titanium Dioxide USP, Hypromellose Type 2910 USP, Polyethylene Glycol 400 NF,  and Polysorbate 80 NF.  </p>
<p>DYNACIN is a registered trademark of Medicis Pharmaceutical Corporation licensed to Par Pharmaceutical, Inc.</p>
<p><span class="Bold">PAR PHARMACEUTICAL COMPANIES, INC.</span></p>
<p>Spring Valley, NY   10977</p>
<p>Revised: 11/2011 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-56e93751-0e50-4853-8da2-09ae25e23301"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL- 50 MG TABLETS</h1>
<div class="Figure">
<a name="ID0EZKBG"></a><img alt="this is the 50mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f174edbd-3ac0-4e27-a116-3b74804721bb&amp;name=50%20mg.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-022639c1-8410-493e-b100-54ec25ae5a9a"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 75 MG TABLETS</h1>
<div class="Figure">
<a name="ID0EOLBG"></a><img alt="this is the 75mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f174edbd-3ac0-4e27-a116-3b74804721bb&amp;name=75mg.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-f09bcc0c-8ee3-412d-aa42-989c2f85f3ef"></a><a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100MG TABLETS</h1>
<div class="Figure">
<a name="ID0EDMBG"></a><img alt="this is the 100mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f174edbd-3ac0-4e27-a116-3b74804721bb&amp;name=100mg.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DYNACINÂ 		
					</strong><br><span class="contentTableReg">minocycline hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-096</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MINOCYCLINE HYDROCHLORIDE</strong> (MINOCYCLINE) </td>
<td class="formItem">MINOCYCLINE</td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Par;511</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-096-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/22/2011</td>
<td class="formItem">02/28/2015</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065131</td>
<td class="formItem">06/20/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DYNACINÂ 		
					</strong><br><span class="contentTableReg">minocycline hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-097</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MINOCYCLINE HYDROCHLORIDE</strong> (MINOCYCLINE) </td>
<td class="formItem">MINOCYCLINE</td>
<td class="formItem">75Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Par;512</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-097-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/22/2011</td>
<td class="formItem">08/31/2015</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065131</td>
<td class="formItem">06/20/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DYNACINÂ 		
					</strong><br><span class="contentTableReg">minocycline hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-098</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MINOCYCLINE HYDROCHLORIDE</strong> (MINOCYCLINE) </td>
<td class="formItem">MINOCYCLINE</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Par;513</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-098-03</td>
<td class="formItem">50  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/22/2011</td>
<td class="formItem">03/31/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065131</td>
<td class="formItem">06/20/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Par Pharmaceutical, Inc.
							(092733690)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Par Pharmaceutical, Inc. (092733690)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Par Pharmaceutical, Inc.</td>
<td class="formItem"></td>
<td class="formItem">092733690</td>
<td class="formItem">MANUFACTURE(49884-096, 49884-097, 49884-098)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3bb7df02-5222-4765-b0ba-2a7c8f41e98d</div>
<div>Set id: f174edbd-3ac0-4e27-a116-3b74804721bb</div>
<div>Version: 4</div>
<div>Effective Time: 20141218</div>
</div>
</div>Â <div class="DistributorName">Par Pharmaceutical, Inc.</div></p>
</body></html>
